TRCT
ALXO icon

Tower Research Capital (TRC)’s ALX Oncology ALXO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,142
Closed -$3.55K – 5099
2025
Q4 		$3.55K Sell
3,142
-696
-18% -$1.05K ﹤0.01% 4351
2025
Q3 		$7.02K Sell
3,838
-6,439
-63% -$5.58K ﹤0.01% 4125
2025
Q2 		$4.27K Sell
10,277
-240
-2% -$121 ﹤0.01% 4352
2025
Q1 		$6.55K Buy
10,517
+5,516
+110% +$6.62K ﹤0.01% 4033
2024
Q4 		$8.35K Sell
5,001
-2,346
-32% -$3.61K ﹤0.01% 3998
2024
Q3 		$13.4K Sell
7,347
-232
-3% -$862 ﹤0.01% 3520
2024
Q2 		$45.7K Buy
7,579
+2,833
+60% +$34.8K ﹤0.01% 3177
2024
Q1 		$52.9K Sell
4,746
-2,815
-37% -$39.5K ﹤0.01% 2238
2023
Q4 		$113K Buy
7,561
+4,120
+120% +$39.1K ﹤0.01% 2561
2023
Q3 		$16.5K Buy
3,441
+1,166
+51% +$6.33K ﹤0.01% 3553
2023
Q2 		$17.1K Sell
2,275
-11,419
-83% -$74.8K ﹤0.01% 3524
2023
Q1 		$62K Buy
13,694
+12,473
+1,022% +$94.5K ﹤0.01% 2306
2022
Q4 		$13K Sell
1,221
-7,979
-87% -$89.6K ﹤0.01% 3570
2022
Q3 		$88K Buy
9,200
+2,110
+30% +$24.6K ﹤0.01% 2667
2022
Q2 		$57K Buy
7,090
+4,226
+148% +$46K ﹤0.01% 2755
2022
Q1 		$48K Sell
2,864
-1,413
-33% -$24.1K ﹤0.01% 2754
2021
Q4 		$92K Buy
4,277
+2,852
+200% +$123K ﹤0.01% 2279
2021
Q3 		$105K Sell
1,425
-205
-13% -$13.7K ﹤0.01% 2354
2021
Q2 		$89K Buy
1,630
+869
+114% +$52K ﹤0.01% 2518
2021
Q1 		$56K Sell
761
-612
-45% -$48.2K ﹤0.01% 3023
2020
Q4 		$118K Sell
1,373
-210
-13% -$12.6K ﹤0.01% 2185
2020
Q3 		$60K Buy
+1,583
New +$62.2K ﹤0.01% 3455

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Tower Research Capital (TRC)'s ALXO Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of ALX Oncology (ALXO) in Q1 2026, closing a stake of 3,142 shares — an estimated $3.55K sold.

Tower Research Capital (TRC) first reported a position in ALXO in Q3 2020 and held it in 22 quarters. The position peaked at $118K in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining ALX Oncology position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,142 ALX Oncology shares in Q1 2026, an estimated $3.55K.
  • Tower Research Capital (TRC) first reported a position in ALX Oncology in Q3 2020 and held it in 22 quarters.
  • Tower Research Capital (TRC)'s ALX Oncology position peaked at $118K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.